Most Read Articles
Pearl Toh, 15 Feb 2019
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Stephen Padilla, 06 Feb 2019
Alirocumab has prevented nonfatal cardiovascular events and deaths, the total of which is twice the number of first events prevented among patients with acute coronary syndrome (ACS) over a median follow-up of 2.8 years, according to results of the ODYSSEY OUTCOMES* trial. In addition, a robust association is seen between the risks of nonfatal and fatal events during the study.
14 Sep 2017
Rifaximin appears to confer increased survival benefit in hepatic encephalopathy patients without hepatocellular carcinoma (HCC), in addition to reducing the risks of spontaneous bacterial peritonitis, variceal bleeding and recurrent hepatic encephalopathy, according to a study.
18 Jan 2019
Azithromycin treatment in children with recurrent asthma-like symptoms acutely disrupts gut microbiota composition, a recent study has found.

Adalimumab dose de-escalation possible in most IBD patients

10 Feb 2019
Crohn’s is not the end of the world, as Kathleen Baker’s silver medal proves

Dose de-escalation of adalimumab to 40 mg every 3 weeks is possible in most of the patients with inflammatory bowel disease (IBD), a recent study has shown.

Researchers conducted a retrospective observational study of 56 IBD patients (median age at diagnosis, 25 years; 44.6 percent male) whose adalimumab doses were de-escalated to 40 mg. De-escalation failure was defined as the need for re-escalation, discontinuation of adalimumab treatment, or biochemical, morphological or clinical disease relapse.

Of the patients, 10 had ulcerative colitis while the remaining 46 had Crohn’s disease. The median time on adalimumab medication before de-escalation was 36 months. At the moment of de-escalation, all of the participants were in clinical remission while most (89.3 percent; n=28) were in biochemical remission.

In more than a third of the cases (37.5 percent; n=21), dose de-escalation was a failure, the median time to which was 8.9 years. In this subgroup of patients, 18 (85.7 percent) underwent dose re-escalation due to insufficient disease control. Seventeen of these patients remained on adalimumab medication at the end of the study duration.

In comparison, two-thirds (62.5 percent; n=35) of the participants successfully underwent dose de-escalation, nine of whom eventually stopped adalimumab medication due to deep remission.

Multivariate Cox analysis showed that the only factor significantly correlated with the risk of failure was having an inactive disease on magnetic resonance imaging and/or endoscopy in the year prior to adalimumab de-escalation (hazard ratio, 0.2; 95 percent CI, 0.1–0.8; p=0.02).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 15 Feb 2019
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Stephen Padilla, 06 Feb 2019
Alirocumab has prevented nonfatal cardiovascular events and deaths, the total of which is twice the number of first events prevented among patients with acute coronary syndrome (ACS) over a median follow-up of 2.8 years, according to results of the ODYSSEY OUTCOMES* trial. In addition, a robust association is seen between the risks of nonfatal and fatal events during the study.
14 Sep 2017
Rifaximin appears to confer increased survival benefit in hepatic encephalopathy patients without hepatocellular carcinoma (HCC), in addition to reducing the risks of spontaneous bacterial peritonitis, variceal bleeding and recurrent hepatic encephalopathy, according to a study.
18 Jan 2019
Azithromycin treatment in children with recurrent asthma-like symptoms acutely disrupts gut microbiota composition, a recent study has found.